Mandate

Vinge advises Boozt AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised Boozt AB (publ) (“Boozt”) in connection with its listing on Nasdaq Stockholm.

The prospectus was published on 17 May 2017 and the first day of trading on Nasdaq Stockholm was 31 May 2017. The price in the offering was SEK 62 per share, corresponding to a market value of Boozt of approximately SEK 3,493 million. The offering comprised 26,015,604 shares, of which 6,451,000 shares were newly issued shares and 19,564,604 were existing shares offered by Sunstone Technology Ventures Fund II K/S, Verdane Capital VII K/S, ECCO Holding A/S, Sampension KP Livsforsikring A/S and the board member Kent Stevens Larsen. The total value of the offering amounted to approximately SEK 1,854 million assuming that the over-allotment option is fully exercised.

Boozt is a leading, fast-growing and profitable Nordic technology company selling fashion online. The Company offers its customers a curated and contemporary selection of fashion brands, relevant to a variety of lifestyles, mainly through its multi-brand webstore Boozt.com. The Company’s webstores attract more than five million sessions per month as a result of a convenient shopping experience with high service levels (including consistent user experiences across both mobile devices and desktop), quick deliveries and easy returns. Boozt targets Nordic fashion followers, primarily consumers aged 25-54 that value convenience in their customer experience and which tend to generate a high average order value.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson, Amanda Knutsson, Filip Brosset, Sara Osman and Josephine Andersson. Joacim Rydergård, Johanna Wiberg and Karl Klackenberg advised on due diligence. Louise Brorsson Salomon and Adam Sandberg advised on financing issues.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026